The Nike Luka 3, Unveiled with Advanced Technology and Sustainability 
PepsiCo Issues Recall for Schweppes Ginger Ale Over Sugar Content 
Why is toddler milk so popular? Follow the money 
PUMA x PlayStation Collaboration Launches with a Fusion of Style and Gaming 
Kakao Games, SM Entertainment Sign Licensing Agreement for Games Featuring K-pop Idol Groups 
Japan Posts 7.7% Growth in Machinery Orders 
Interest rates are expected to drop but trying to out-think the market won’t guarantee getting a good deal 
Food Firms in Korea Such as Popeyes, Goobne Resume Price Hikes After Elections 
Germany's Largest Federal Bank, Landesbank Baden-Württemberg, Teams with Bitpanda for Crypto Custody Services 
Vladimir Putin’s gold strategy explains why sanctions against Russia have failed 
Nike Innovates for Mothers with New Apparel and Footwear 
Pay Blockchain Fees with Klever KDA Tokens 
An education in music makes you a better employee. Are recruiters in tune? 
Food prices will climb everywhere as temperatures rise due to climate change – new research 
Industry shutdowns are messy and painful: 4 lessons Australia’s coal sector can learn from car-makers about bowing out 
Adobe Unveils Acrobat AI Assistant Tool for Acrobat and Reader Users 
Celltrion biopharmaceutical company based in Incheon, South Korea, has become the largest shareholder in United Kingdom’s Iksuda Therapeutics biotech firm. This happened after the former acquired more stake in the antibody-drug conjugates (ADCs) developer’s company.
According to The Korea Herald, Celltrion now owns a 47.05% stake in Iksuda Therapeutics. It was able to buy more shares after securing a new growth fund. The South Korean leading drugmaker announced its latest acquisition on Wednesday, Jan. 25.
Celltrion shared it paid for the asset through direct investment and a fund it set up with Mirae Asset Capital. With the deal, Celltrion and the Mirae Asset Celltrion New Growth Fund are now the largest co-shareholders of Iksuda Therapeutics. The initial share that Celltrion owned prior to the new investment is unknown, as the company reportedly declined to say.
Moreover, the investment was made under the same contract terms that Celltrion and Mirae Asset Capital signed before. In the deal, they agreed to invest a total of KRW58 billion or about $47 million when they participated in the British biotech firm’s Series A financing round that took place in June 2021, as per The Korea Economic Daily.
With its increased share in Iksuda Therapeutics, Celltrion now expects to transform and expand its anti-cancer treatments by using the latter’s ADC technology for its biosimilar products - Herzuma and Truxima.
“We are working with and investing in various biotechnologies with promising platforms. We will be taking versatile measures to increase our influence in the growing ADC field,” the company said in a statement.
Iksuda Therapeutics mainly works on the development of the next-generation ADC for incurable cancer drugs. This is an anti-cancer tech that has been receiving a lot of attention recently because it was able to specifically attack cancer cells by simply connecting antibody drugs and chemical anti-cancer medicines.
